A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

Documenti analoghi

• A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer
  di: Nielsen, Torsten O., et al.
  Pubblicazione: (2010)
• RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.
  di: Dana Keilty, et al.
  Pubblicazione: (2013-01-01)
• RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial
  di: Keilty, Dana, et al.
  Pubblicazione: (2013)
• Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
  di: Cheang, Maggie C.U., et al.
  Pubblicazione: (2012)
• Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
  di: Cheang, Maggie C.U., et al.
  Pubblicazione: (2015)